found that GLP-1 receptor agonist use, compared with initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors, was associated with a lower risk of composite MALOs (aHR: 0.84, 95%CI: 0.74-0.94), including specifically lower occurrence of liver decompensation (aHR: 0.83) and all-cause mortality (aHR: 0.84) [56]
The E3 ligase acts as a docking platform to attach the Ub-containing E2 enzyme to a particular substrate, enabling the Ub to bind to the lysine residue of the substrate protein
S = selection of patients initiating semaglutide, tirzepatide, dulaglutide, or sitagliptin (as a placebo proxy) via propensity score 1:1 nearest neighbor matching to mimic randomization
If it is time for your next dose, skip the missed dose
This product has not been evaluated by the Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease or condition